2023 Fiscal Year Final Research Report
Externally Triggered Nanomachine for Breast Cancer Theranostics
Project/Area Number |
20K05260
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 28030:Nanomaterials-related
|
Research Institution | Gunma National College of Technology (2021-2023) Saitama University (2020) |
Principal Investigator |
|
Project Period (FY) |
2020-04-01 – 2024-03-31
|
Keywords | Nanomedicine / Nanomachines / Drug delivery systems / CAR T Immunotherapy / Adoptive therapy / Noninvasive chemotherapy / Nanozyme / Cancer |
Outline of Final Research Achievements |
Programmable nanodevices engineered for external activation were designed to facilitate cancer diagnosis and therapeutic treatment. Artificial nanozyme employing carbon nanodots was highlighted as a versatile platform for theranostic nanomachines. It integrates logic control systems, leveraging fluorescent responses to chemical or biological stimuli. This platform exhibits effectiveness in inhibiting breast cancer cells and regulating their metastatic migration through NIR irradiation, suggesting applications in photothermal and photodynamic therapy. Under normoxic conditions, the nanozymes regulate metastatic migration while demonstrating biocompatibility across various cellular assays. The therapeutic dosage was remarkably low, with no discernible adverse effects on healthy cellular pathways. The developed nanodevices were capable to reshape the tumor microenvironment, thereby establishing a therapeutic opportunity for effective adoptive therapy in treating of solid malignancies.
|
Free Research Field |
Nanotechnology
|
Academic Significance and Societal Importance of the Research Achievements |
The scientific significance is underscored by the advancement of innovative programmable nanodevices which serve as a versatile theranostic platform, offering effective strategies for cancer treatment. The social significance is tied to the achievement of enhanced cancer diagnosis and medication.
|